Patients | Controls | Adjusted OR (95% CI)1 | ||||||
---|---|---|---|---|---|---|---|---|
(n = 325) | (n = 335) | |||||||
Variables | HPV16 Status | No. | % | No. | % | OSCC | SCCOP | Oral cavity |
TNF-α-308 | ||||||||
GG | − | 70 | 21.5 | 109 | 32.5 | 1.0 | 1.0 | 1.0 |
GA + AA | − | 155 | 47.7 | 184 | 54.9 | 1.3 (1.0 − 1.9) | 1.4 (1.0 − 2.3) | 0.4 (0.1 − 1.5) |
GG | + | 31 | 9.5 | 19 | 5.7 | 2.5 (1.3 − 4.8) | 4.6 (2.2 − 9.5) | 1.1 (0.7 − 1.8) |
GA + AA | + | 69 | 21.2 | 23 | 6.9 | 4.8 (2.7 − 8.4) | 9.3 (4.9 − 17.6) | 1.2 (0.5 − 2.8) |
TNF-α-857 | ||||||||
CC | − | 198 | 60.9 | 261 | 77.9 | 1.0 | 1.0 | 1.0 |
CT + TT | − | 27 | 8.3 | 32 | 9.6 | 1.2 (0.7 − 2.1) | 1.4 (0.7 − 2.7) | 0.7 (0.3 − 1.4) |
CC | + | 85 | 26.2 | 38 | 11.3 | 3.0 (2.0 − 4.7) | 5.6 (3.5 − 9.0) | 1.0 (0.5 − 1.9) |
CT + TT | + | 15 | 4.6 | 4 | 1.2 | 5.3 (1.7 − 16.2) | 9.3 (3.0 − 29.6) | 1.5 (0.3 − 8.6) |
TNF-α-863 | ||||||||
CC | − | 66 | 20.31 | 115 | 34.3 | 1.0 | 1.0 | 1.0 |
CA + AA | − | 159 | 48.9 | 178 | 53.1 | 1.6 (1.1 − 2.3) | 1.8 (0.8 − 2.2) | 0.8 (0.3 − 2.4) |
CC | + | 34 | 10.5 | 19 | 5.7 | 3.1 (1.6 − 5.9) | 5.2 (2.5 − 10.5) | 1.7 (1.0 − 2.7) |
CA + AA | + | 66 | 20.3 | 23 | 6.9 | 5.3 (3.0 − 9.4) | 8.5 (4.6 − 16.0) | 1.3 (0.5 − 3.2) |
TNF-α-1031 | ||||||||
TT | − | 71 | 21.9 | 115 | 34.3 | 1.0 | 1.0 | 1.0 |
TC + CC | − | 154 | 47.4 | 178 | 53.1 | 1.4 (1.0 − 2.0) | 1.6 (1.0 − 2.6) | 0.7 (0.2 − 2.3) |
TT | + | 31 | 9.5 | 17 | 5.1 | 3.1 (1.6 − 6.1) | 6.0 (2.8 − 12.4) | 1.2 (0.8 − 2.0) |
TC + CC | + | 69 | 21.2 | 25 | 7.5 | 4.5 (2.6 − 7.9) | 9.0 (4.8 − 16.7) | 1.0 (0.4 − 2.3) |